Concepedia

Cyteir Therapeutics (United States)

CT

Statistics

Publications

24

Citations

387

Authors

2

Location

Lexington, United States

Cyteir Therapeutics (United States) is a company institution in Lexington, United States.

HomepageROR

Publications

24

Genetic and Small Molecule Disruption of the AID/RAD51 Axis Similarly Protects Nonobese Diabetic Mice from Type 1 Diabetes through Expansion of Regulatory B Lymphocytes

Jeremy Ratiu, Jeremy J. Racine, Muneer G. Hasham et al. · The Journal of Immunology · 2017 · 36 citations · Full text

First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.

Ryan C. Lynch, Johanna C. Bendell, Ranjana H. Advani et al. · Journal of Clinical Oncology · 2021 · 21 citations

Enhancing the efficacy of glycolytic blockade in cancer cells<i>via</i>RAD51 inhibition

John J. Wilson, Kin-Hoe Chow, Nathan J. Labrie et al. · Cancer Biology & Therapy · 2018 · 14 citations · Full text

1–3 of 24

Authors

2

  1. EW
    Elise W. Wolf

    Cyteir Therapeutics (United States), United States

    5 publications · 35 citations

    3

    h-index

  2. NJ
    Nathan J. Labrie

    Cyteir Therapeutics (United States), United States

    2 publications · 14 citations

    1

    h-index

1–2 of 2